Evermay Wealth Management’s Sarepta Therapeutics SRPT Stock Holding History

Evermay Wealth Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-60	Closed	-$1.29K	–	616
2025 Q4	$1.29K	Hold	60	–	–	﹤0.01%	529
2025 Q3	$1.16K	Sell	60 -90	-60%	-$1.6K	﹤0.01%	510
2025 Q2	$2.56K	Buy	150 +90	+150%	+$3.84K	﹤0.01%	494
2025 Q1	$3.83K	Hold	60	–	–	﹤0.01%	495
2024 Q4	$7.3K	Hold	60	–	–	﹤0.01%	469
2024 Q3	$7.49K	Hold	60	–	–	﹤0.01%	479
2024 Q2	$9.48K	Hold	60	–	–	﹤0.01%	461
2024 Q1	$7.77K	Hold	60	–	–	﹤0.01%	487
2023 Q4	$5.79K	Hold	60	–	–	﹤0.01%	479
2023 Q3	$7.27K	Hold	60	–	–	﹤0.01%	453
2023 Q2	$6.87K	Hold	60	–	–	﹤0.01%	450
2023 Q1	$8.27K	Hold	60	–	–	﹤0.01%	434
2022 Q4	$7.78K	Hold	60	–	–	﹤0.01%	436
2022 Q3	$7K	Hold	60	–	–	﹤0.01%	433
2022 Q2	$4K	Hold	60	–	–	﹤0.01%	449
2022 Q1	$5K	Hold	60	–	–	﹤0.01%	458
2021 Q4	$5K	Hold	60	–	–	﹤0.01%	453
2021 Q3	$6K	Hold	60	–	–	﹤0.01%	409
2021 Q2	$5K	Buy	+60	New	+$4.55K	﹤0.01%	452

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Evermay Wealth Management's SRPT Position: Q1 2026 in Review

Evermay Wealth Management sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 60 shares — an estimated $1.29K sold.

Evermay Wealth Management first reported a position in SRPT in Q2 2021 and held it in 19 quarters. The position peaked at $9.48K in Q2 2024. 344 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

Evermay Wealth Management reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
Evermay Wealth Management sold 60 Sarepta Therapeutics shares in Q1 2026, an estimated $1.29K.
Evermay Wealth Management first reported a position in Sarepta Therapeutics in Q2 2021 and held it in 19 quarters.
Evermay Wealth Management's Sarepta Therapeutics position peaked at $9.48K in Q2 2024.
344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Evermay Wealth Management's 13F filing for Q1 2026, filed 12 May 2026.